Ipsen licenses MSD's Adrovance in France
Paris, France-based drugmaker Ipsen has licensed the domestic co-marketing rights to Adrovance, its fixed combination of alendronate sodium and cholecalciferol (vitamin D3), from MSD, a unit of US drug major Merck & Co.
Indicated for the treatment of postmenopausal osteoporosis in patients at risk of vitamin D deficiency, Adrovance reduces the risk of vertebral and hip fractures. MSD currently markets this product under the brand name Fosavance.
Under the terms of the deal, Ipsen will source the product from MSD, market and sell it under the brand name Adrovance in France. Financial details were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze